Orion Corporation: Recent Management Transactions Overview
Orion Corporation is widely recognized for its remarkable contributions to the pharmaceutical industry, standing strong for over a century as a driver of well-being across the globe. Recently, the company underwent significant managerial transactions, shedding light on the financial activities of its upper management. The latest reports include a transaction by Karen Lykke Sørensen, a key member of the board.
Transaction Details of Karen Lykke Sørensen
According to the disclosure received under the Market Abuse Regulation (EU) No 596/2014, Orion Corporation reported important transactions executed by its managers and their closely related associates. In this instance, Karen Lykke Sørensen is noted for her recent stock transaction.
Important Notification Information
Karen Lykke Sørensen holds the position of a Member of the Board and Deputy member. The essential notification details are as follows:
- Issuer: Orion Oyj
- LEI: 74370029VAHCXDR7B745
- Notification Type: Initial Notification
- Reference Number: 106240/5/4
Transaction Overview
The transaction details reveal that, on April 30, a total of 415 shares were received as part of a share-based incentive. Despite the absence of a definitive monetary value, the collective aggregation indicated a volume-weighted average price of 0 EUR.
Broader Context: Orion's Market Position
Orion Corporation operates as a key player in the global pharmaceutical market, focusing on research and development in critical areas such as oncology and pain management. The company is dedicated to producing a vast range of pharmaceuticals, both proprietary and generic, along with active pharmaceutical ingredients.
Financial Performance and Employment
In the previous financial year, Orion's net sales impressively reached EUR 1,542 million. With approximately 3,700 skilled professionals on staff, the commitment to fostering well-being remains paramount to Orion's mission.
Future Prospects and Strategic Goals
As Orion continues to innovate and expand its product offerings, the management team remains focused on enhancing their extensive portfolio. With therapeutic developments aimed at treating various serious conditions such as cancer and respiratory diseases, the outlook for Orion Corporation stays positive.
Contact Information
For any inquiries or further information, please reach out to Orion Corporation's communications department, located at Orionintie 1A, FI-02200 Espoo, Finland. Their commitment to transparency is evident in their communications, where they encourage relevant engagement regarding their stock transactions and overall company activities.
Frequently Asked Questions
What recent transactions occurred at Orion Corporation?
Orion Corporation reported a share-based incentive transaction involving Karen Lykke Sørensen, a board member, who received 415 shares on April 30.
What is the significance of the Market Abuse Regulation?
The Market Abuse Regulation is designed to maintain market integrity by ensuring transparency regarding transactions made by individuals in key positions within publicly listed companies.
How does Orion Corporation contribute to the pharmaceutical industry?
With a rich history exceeding a hundred years, Orion Corporation develops and markets a range of pharmaceuticals focusing on human and veterinary health.
What are Orion’s main therapeutic areas?
Orion primarily focuses on oncology and pain management, working on innovative treatments for various serious conditions.
Where can I find more information about Orion Corporation?
Additional information about Orion Corporation, including its products and financial performance, can be found on their official website.
